CVS vs HUM: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: CVS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CVS and HUM share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CVS and HUM exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

CVS Health runs three reporting segments. Health Care Benefits is the Aetna insurance business, which earns premiums from roughly 26 million medical members and profits when claims (the medical benefit ratio) stay below what it collects. Health Services is built around the Caremark pharmacy benefit manager, which negotiates drug prices and manages pharmacy claims for health plans and employers and generated over $48 billion of revenue in Q1 2026. Pharmacy and Consumer Wellness is the familiar retail footprint of CVS drugstores, which makes money filling prescriptions and selling front-of-store health and consumer goods, with same-store prescription volumes up nearly 7% in Q1 2026.

Full CVS guide

Humana Inc. is a Louisville-based health and well-being company best known as one of the two largest Medicare Advantage insurers in the country, alongside UnitedHealth. Its Insurance segment covers roughly 7.1 million individual and group Medicare Advantage members as of early 2026, plus Medicaid, military (TRICARE), and pharmacy-benefit members. The core economics turn on the medical loss ratio, the share of premium dollars paid out as medical claims, and on CMS star ratings, which determine quality-bonus payments that fund richer plan benefits.

Full HUM guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CVS drivers: Integrated model under one roof; Turnaround and improving Aetna margins.
• HUM drivers: Demographic tailwind in Medicare Advantage; CenterWell healthcare services.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The clearest risk is the medical-cost trend at Aetna: if claims reaccelerate, especially in Medicare Advantage, earnings can fall faster than premiums can be re-priced, which is what drove the 2023 to 2024 decline. For HUM, the medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove recent earnings pressure.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CVS if you believe its drivers more; HUM if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CVS and HUM guides.

CVS. CVS trades at a low forward earnings multiple versus the broad market, which reflects lingering caution after the 2023 to 2024 Aetna downturn rather than current results. The value angle rests on whether improving margins and ~$400 billion of revenue can support the raised guidance. Figures are approximate and tied to the asOf date; verify live quotes and the latest filings before acting.

HUM. These figures are approximate and tied to the June 2026 asOf date; insurer earnings can move sharply quarter to quarter with the medical-cost trend, and the trailing P/E looks high mainly because recent profits are depressed. Check Humana's latest filings and a current quote before relying on any single number.

Headline figures (approximate, 2026-06-27): CVS shows revenue (annual run-rate) ~$400 billion; FY2026 guidance at least ~$405 billion, adjusted eps (fy2026 guidance) ~$7.30 to $7.50 (Q1 2026 was ~$2.57), aetna medical benefit ratio (q1 2026) ~84.6%, improved from ~87.3% a year earlier, dividend yield ~2.5% (~$2.66 annual, ~$0.665 quarterly); HUM shows revenue (ttm) ~$130 billion, adjusted eps (2026 guidance) ~$9.00 or more, medical loss ratio (2026 outlook) ~92.75%, dividend yield ~1.5%.

CVS and HUM are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CVS and HUM exposure against your real portfolio. It is not an investment adviser.